NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Lava Therapeutics announces initial data from the ongoing phase 1/2a clinical trial of LAVA-1207 in therapy refractory MCRPC at the 2023 ASCO GU symposium<
16 Feb 2023

Lava Therapeutics announces initial data from the ongoing phase 1/2a clinical trial of LAVA-1207 in therapy refractory MCRPC at the 2023 ASCO GU symposium

Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicities
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administrationat the Macula Society 46th Annual Meeting<
16 Feb 2023

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administrationat the Macula Society 46th Annual Meeting

These latest results strongly support the potential of bel-sar to be used as a first line treatment option for patients with early-stage choroidal melanoma
Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares<
15 Feb 2023

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The aggregate gross proceeds from the offering were $220.8 million, before deducting underwriting discounts and commissions and other offering expenses
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering<
14 Feb 2023

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $192.0 million
Lava Therapeutics announces the appointment of Dr. Charles Morris as Chief Medical Officer<
06 Feb 2023

Lava Therapeutics announces the appointment of Dr. Charles Morris as Chief Medical Officer

Dr. Morris is a medical oncologist with over 25 years of oncology drug development experience
VarmX appoints Paul Roos as Chief Financial Officer<
31 Jan 2023

VarmX appoints Paul Roos as Chief Financial Officer

Paul has a wealth of experience in the international life sciences industry and investment banking
Ysios Capital strengthens its team with internal promotions and a new Venture Partner<
19 Jan 2023

Ysios Capital strengthens its team with internal promotions and a new Venture Partner

These appointments add operational capacities supporting Ysios’ mission to build leading life sciences companies.
The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy<
19 Jan 2023

The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy

Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions
LAVA Therapeutics Announces Appointment of New Directors to the Board<
06 Jan 2023

LAVA Therapeutics Announces Appointment of New Directors to the Board

Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board.
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes<
05 Jan 2023

NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH  expected in Q1 2023  

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.